$231.8 million U.S. funding awarded to Ellume COVID-19 Home Test that integrates
AnteoBind™ for superior sensitivity
AnteoTech’s long-term customer Ellume, producer of next-generation digitally enabled diagnostic solutions, has secured a $231.8 million agreement with the U.S. Government to support accelerated manufacture of its COVID-19 home test. The test makes use of AnteoTech’s unique AnteoBind™ technology to support significantly improved sensitivity, and is the first rapid self-test for SARS-CoV-2 detection authorized by the United States Food and Drug Administration (FDA) for use without a prescription. Through the patented AnteoBind technology and the expertise and know-how delivered via its Contract Services in assay development and bioconjugation, AnteoTech continues to address the pressing challenges of the point-of-care diagnostics, biopharmaceutical and vaccine development markets.
With the help of AnteoTech’s AnteoBind technology, the Ellume COVID-19 Home Test provides accurate results in 15 minutes or less, detecting SARS-CoV-2 in both symptomatic and asymptomatic individuals. Ellume’s offering is the first test which utilizes AnteoBind to receive FDA Emergency Use Authorization (EUA).“With the Ellume test receiving FDA authorization and subsequent significant financial backing from the U.S. Government, this is further evidence of the immense value the AnteoBind technology continues to bring to the life sciences industry for life-changing solutions,” said Derek Thomson, Chief Executive Officer of AnteoTech. “The capabilities of high-sensitivity diagnostics, such as Ellume’s COVID-19 Home Test, will ultimately enable rapid and reliable screening to minimize community spread, relieve burden on healthcare systems and facilitate the reopening of economies.”
AnteoBind is a nano-sized molecular glue used to facilitate simpler, faster and more reliable bioconjugation. The improved conjugation process increases the performance for diagnostic assays, and enables superior quality control, candidate screening and efficacy-measurement processes in biopharmaceutical and vaccine development. The Ellume COVID-19 Home Test is an example of how AnteoBind technology can aid in delivering conjugation stability, unmatched sensitivity and batch-to-batch reproducibility – all while being manufactured at scale.
Dr. Sean Parsons, Chief Executive Officer of Ellume, said “Our recent Emergency Use Authorization was a key milestone in our mission to make a significant contribution to global health. AnteoTech’s AnteoBind has greatly assisted us in the development of a highly sensitive test that is vital for an effective COVID-19 mitigation strategy. We look forward to our continued partnership with AnteoTech as we deliver accurate diagnostic solutions to the market.”
AnteoTech’s AnteoBind can be purchased directly as an AnteoBind-based ready-to-use kit to streamline and improve the conjugation process, or is available through AnteoTech’s Assay Development Services. The Assay Development Services are focused on the application of AnteoBind, and draw on the AnteoTech team’s extensive biomedical research and assay development experience, particularly in difficult conjugation assay design and quantitative assay design.
For more information on AnteoTech’s AnteoBind technology and Contract Services, please visit: https://www.anteotech.com/life-science/anteobind/.
About AnteoTech Ltd.
AnteoTech is a surface chemistry company with Intellectual Property in its core technology product groups AnteoBindTM, AnteoCoatTM, and AnteoReleaseTM. The company is committed to creating shareholder value by identifying and solving critical global industry problems through unique value-add solutions. AnteoTech serves companies in the life sciences, diagnostics and energy markets.